financetom
Business
financetom
/
Business
/
Petco Health & Wellness Fiscal Q4 Loss Narrows, Revenue Falls; Shares Rise After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Petco Health & Wellness Fiscal Q4 Loss Narrows, Revenue Falls; Shares Rise After Hours
Mar 11, 2026 2:00 PM

04:34 PM EDT, 03/11/2026 (MT Newswires) -- Petco Health & Wellness (WOOF) reported fiscal Q4 net loss late Wednesday of $0.01 per diluted share, narrowing from a loss of $0.05 a year earlier.

Analysts polled by FactSet expected earnings of $0.01.

Revenue for the quarter ended January 31 was $1.52 billion, down from $1.55 billion a year earlier.

Analysts polled by FactSet expected $1.51 billion.

For fiscal Q1, the company sees revenue down 1% to flat year over year. For fiscal 2026, the company expects revenue to be flat to up 1.5% year over year. Analysts polled by FactSet are looking for revenue of $1.49 billion for fiscal Q1 and $5.99 billion for fiscal 2026.

Shares of the company rose nearly 12% in after-hours activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Tariffs have cost Volkswagen 'several billions' so far, CEO says
Tariffs have cost Volkswagen 'several billions' so far, CEO says
Sep 8, 2025
* CEO says Porsche brand in 'sandwich' between China, tariffs * Volkswagen in talks with Washington over investment tax breaks * Undecided whether Blume will give up VW or Porsche CEO role (Adds context in paragraph 3-4, CEO comments in paragraphs 7, 10) By Christoph Steitz and Louisa Off MUNICH, Sept 8 (Reuters) - U.S. tariffs have cost Volkswagen, Europe's...
Ideaya Biosciences, Partner Say Small Cell Lung Cancer Therapy Shows Promising Early Data
Ideaya Biosciences, Partner Say Small Cell Lung Cancer Therapy Shows Promising Early Data
Sep 8, 2025
04:17 AM EDT, 09/08/2025 (MT Newswires) -- Ideaya Biosciences ( IDYA ) and Hengrui Pharma said Sunday that initial data from a phase 1 trial of the experimental IDE849 small cell lung cancer treatment showed strong overall response and disease control rates across all tested doses and stages of treatment, with only a modest decline in later-line patients, an expected...
AstraZeneca Says Tagrisso Combination Therapy Demonstrates Superior Overall Survival in Late-Stage Trial
AstraZeneca Says Tagrisso Combination Therapy Demonstrates Superior Overall Survival in Late-Stage Trial
Sep 8, 2025
04:27 AM EDT, 09/08/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday that results from a phase 3 trial of Tagrisso plus pemetrexed and platinum-based chemotherapy showed statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival compared with Tagrisso alone in patients with non-small cell lung cancer. The Tagrisso combination therapy showed a median...
BRIEF-Strathcona Resources Announces Amended And Extended Offer To Acquire Meg Energy Corp
BRIEF-Strathcona Resources Announces Amended And Extended Offer To Acquire Meg Energy Corp
Sep 8, 2025
Sept 8 (Reuters) - STRATHCONA RESOURCES ( STHRF ): * STRATHCONA RESOURCES ( STHRF ) - MEG BOARD DEAL IS UNFAIR TO MEG SHAREHOLDERS AND RESULT OF A BROKEN SALE PROCESS * STRATHCONA RESOURCES LTD. ( STHRF ) ANNOUNCES AMENDED AND EXTENDED OFFER TO ACQUIRE MEG ENERGY CORP. * STRATHCONA RESOURCES LTD ( STHRF ) - AMENDED OFFER EQUATES TO...
Copyright 2023-2026 - www.financetom.com All Rights Reserved